ASPR releases strategy enabling a successful HHS response to H5N1

The Administration for Strategic Preparedness and Response (ASPR), through the Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services (HHS), is announcing the Pandemic Influenza Preparedness and Response Strategy. BARDA will leverage existing infrastructures and capabilities to respond to the current Highly Pathogenic Avian Influenza (HPAI) H5N1 threat while continuing to establish new capabilities to improve rapid response to both the current H5N1 virus and other potential pandemic influenza viruses in the future. This strategy outlines BARDA’s objectives for enabling a successful HHS response to H5N1.

BARDA has grouped the strategy into four objectives, each with current activities and future priorities: Objectives:

• Objective 1: Strategic implementation and deployment of the U.S. National Pre-pandemic Influenza Vaccine Stockpile (NPIVS).
• Objective 2: Enhanced protection through novel vaccines against pandemic influenza.
• Objective 3: Leverage therapeutics through deployment, early availability, and development of novel products.
• Objective 4: Ensure rapid and effective diagnostics tools to inform rapid antiviral prescription and treatment.

BARDA’s activities are a part of a larger HHS influenza research strategy and are a regular aspect of ASPR’s preparedness responsibilities. The agency’s mission is to assist the country in preparing for, responding to, and recovering from public health emergencies and disasters. ASPR has subject matter experts available to discuss the agenda in greater detail upon request. Additional information about ASPR response operations can be found at aspr.hhs.gov/H5N1.